AR070951A1 - INDANO COMPOUNDS, THEIR USES FOR THE PREPARATION OF MEDICINES AND THEIR USES FOR THE TREATMENT OF MELATONINERGIC ALTERATIONS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM - Google Patents

INDANO COMPOUNDS, THEIR USES FOR THE PREPARATION OF MEDICINES AND THEIR USES FOR THE TREATMENT OF MELATONINERGIC ALTERATIONS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM

Info

Publication number
AR070951A1
AR070951A1 ARP080104619A ARP080104619A AR070951A1 AR 070951 A1 AR070951 A1 AR 070951A1 AR P080104619 A ARP080104619 A AR P080104619A AR P080104619 A ARP080104619 A AR P080104619A AR 070951 A1 AR070951 A1 AR 070951A1
Authority
AR
Argentina
Prior art keywords
ethyl
indan
methoxy
propionamide
phenyl
Prior art date
Application number
ARP080104619A
Other languages
Spanish (es)
Inventor
Albert Palomer
Antonio Guglietta
Josep Lluis Falco
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of AR070951A1 publication Critical patent/AR070951A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Compuestos de indano que se seleccionan del grupo consistente en: 1) N-[2-(6-metoxi-indan-1-il)-propil]-acetamida; 2) N-[2-(2-bencil-6-metoxi-indan-1-il)etil]-acetamida, 3) N-[2-(2-etil-6-metoxi-indan-1-il)-etil]-propionamida, 4) N-[2-(6-metoxi-2-propil-indan-1-il)-etil]-propionamida, 5) N-[2-(6-metoxi-2-fenil-indan-1-il)-etil]-propionamida, 6) N-[2-(6-metoxi-indan-1-il)etil]-butiramida, 7) N-[2-(6-metoxi-3-metil-indan-1-il)-etil]-propionamida, 8) N-[2-(6-metoxi-3-metil-indan-1-il)]-etil-acetamida, 9) 1-etil-3-[2-(6-metoxi-3-metil-indan-1-il)-etil]-urea, 10) N-[2-(6-metoxi-3-metil-indan-1-il)-etil]-2,2-dimetil-propionamida, 11) -2-(6-metoxi-3-metil-indan-1-il)-etil]-ciclopropancarboxamida, 12) N-[2-(5-bromo-6-metoxi-indan-1-il)-etil]-propionamida, 13) N-[2-(6-metoxi-5-fenil-indan-1-il)-etil]-propionamida, 14) N-[2-(6-metoxi-5-p-tolil-indan-1-il)-etil]-propionamida, 15) N-[2-(6-metoxi-5-(4-metoxi-fenil)-indan-1-il)-etil]-propionamida, 16) N-{2-[5-(3,5-dimetil-isoxazol-4-il)-6-metoxi-indan-1-il]-etil}-propionamida, 17) N-[2-(6-metoxi-5-piridin-4-il-indan-1-il)-etil]-propionamida, 18) N-[2-(5-furan-2-il-6-metoxi-indan-1-il)-etil]-propionamida, 19) N-[2-(6-fenetiloxi-indan-1-il)-etil]-propionamida, 20) N-{2-[6-(4-fenil-butoxi)-indan-1-il]-etil}-propionamida, 21) N-{2-[6-(4-fenil-butoxi)-indan-1-il]-etil}-acetamida, 22) 1-etil-3-{2-[6-(4-fenil-butoxi)-indan-1-il]-etil]-urea y 23) {2-[6-(4-fenil-butoxi)-indan-1-il]-etil}-carbamato de metilo y sus sales e hidratos farmacéuticamente aceptables. Sus usos para la preparacion de un medicamento y para el tratamiento o la prevencion de las alteraciones melatoninérgicas, seleccionadas del grupo de: la depresion, el stress, las alteraciones del sueno, la ansiedad, los trastornos afectivos estacionales, la patología cardiovascular, la patología del sistema digestivo, el insomnio o la fatiga debidos al ôjet lagö, la esquizofrenia, los ataques de pánico, la melancolía, las alteraciones del apetito, la obesidad, el insomnio, las enfermedades psicoticas, la epilepsia, la diabetes, la enfermedad de Parkinson, a demencia senil, las alteraciones asociadas con el envejecimiento normal o patologico, la migrana, la pérdida de memoria, la enfermedad de Alzheimer y las alteraciones de la circulacion cerebral.Indane compounds that are selected from the group consisting of: 1) N- [2- (6-methoxy-indan-1-yl) -propyl] -acetamide; 2) N- [2- (2-Benzyl-6-methoxy-indan-1-yl) ethyl] -acetamide, 3) N- [2- (2-ethyl-6-methoxy-indan-1-yl) - ethyl] -propionamide, 4) N- [2- (6-methoxy-2-propyl-indan-1-yl) -ethyl] -propionamide, 5) N- [2- (6-methoxy-2-phenyl-indan -1-yl) -ethyl] -propionamide, 6) N- [2- (6-methoxy-indan-1-yl) ethyl] -butyramide, 7) N- [2- (6-methoxy-3-methyl- indan-1-yl) -ethyl] -propionamide, 8) N- [2- (6-methoxy-3-methyl-indan-1-yl)] - ethyl-acetamide, 9) 1-ethyl-3- [2 - (6-methoxy-3-methyl-indan-1-yl) -ethyl] -urea, 10) N- [2- (6-methoxy-3-methyl-indan-1-yl) -ethyl] -2, 2-dimethyl-propionamide, 11) -2- (6-methoxy-3-methyl-indan-1-yl) -ethyl] -cyclopropancarboxamide, 12) N- [2- (5-bromo-6-methoxy-indan- 1-yl) -ethyl] -propionamide, 13) N- [2- (6-methoxy-5-phenyl-indan-1-yl) -ethyl] -propionamide, 14) N- [2- (6-methoxy- 5-p-tolyl-indan-1-yl) -ethyl] -propionamide, 15) N- [2- (6-methoxy-5- (4-methoxy-phenyl) -indan-1-yl) -ethyl] - propionamide, 16) N- {2- [5- (3,5-dimethyl-isoxazol-4-yl) -6-methoxy-indan-1-yl] -ethyl} -propionamide, 17) N- [2- ( 6-methoxy-5-pyridin-4-yl-indan-1-yl) -ethyl] -propionamide, 18) N- [2- (5-furan-2- il-6-methoxy-indan-1-yl) -ethyl] -propionamide, 19) N- [2- (6-phenethyloxy-indan-1-yl) -ethyl] -propionamide, 20) N- {2- [ 6- (4-phenyl-butoxy) -indan-1-yl] -ethyl} -propionamide, 21) N- {2- [6- (4-phenyl-butoxy) -indan-1-yl] -ethyl} - acetamide, 22) 1-ethyl-3- {2- [6- (4-phenyl-butoxy) -indan-1-yl] -ethyl] -urea and 23) {2- [6- (4-phenyl-butoxy ) -indan-1-yl] -ethyl} -methylcarbamate and its pharmaceutically acceptable salts and hydrates. Its uses for the preparation of a drug and for the treatment or prevention of melatoninergic disorders, selected from the group of: depression, stress, sleep disturbances, anxiety, seasonal affective disorders, cardiovascular pathology, pathology of the digestive system, insomnia or fatigue due to ôjet lagö, schizophrenia, panic attacks, melancholy, appetite disturbances, obesity, insomnia, psychotic diseases, epilepsy, diabetes, Parkinson's disease , to senile dementia, the alterations associated with normal or pathological aging, migraine, memory loss, Alzheimer's disease and alterations of cerebral circulation.

ARP080104619A 2007-10-25 2008-10-23 INDANO COMPOUNDS, THEIR USES FOR THE PREPARATION OF MEDICINES AND THEIR USES FOR THE TREATMENT OF MELATONINERGIC ALTERATIONS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM AR070951A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200702797A ES2324849A1 (en) 2007-10-25 2007-10-25 Indane compounds

Publications (1)

Publication Number Publication Date
AR070951A1 true AR070951A1 (en) 2010-05-19

Family

ID=40347968

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104619A AR070951A1 (en) 2007-10-25 2008-10-23 INDANO COMPOUNDS, THEIR USES FOR THE PREPARATION OF MEDICINES AND THEIR USES FOR THE TREATMENT OF MELATONINERGIC ALTERATIONS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM

Country Status (6)

Country Link
AR (1) AR070951A1 (en)
CL (1) CL2008003138A1 (en)
ES (1) ES2324849A1 (en)
TW (1) TW200934477A (en)
UY (1) UY31422A1 (en)
WO (1) WO2009053443A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2758041B1 (en) 2011-09-20 2021-01-13 Basf Se Low-molecular modulators of the cold-menthol receptor trpm8 and use of same
CN103193668B (en) * 2013-03-19 2016-01-20 华东师范大学 Chiral indan derivant and its production and use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
EP0781271B1 (en) * 1994-09-12 2000-06-07 Takeda Chemical Industries, Ltd. Benzocycloalkene compounds, their production and use
US5661186A (en) * 1995-02-24 1997-08-26 Bristol-Myers Squibb Co. Tetralinyl-and indanyl-ethylamides
EP1550655A1 (en) * 1996-03-08 2005-07-06 Takeda Pharmaceutical Company Limited Bicyclic intermediates

Also Published As

Publication number Publication date
WO2009053443A2 (en) 2009-04-30
UY31422A1 (en) 2009-04-30
ES2324849A1 (en) 2009-08-17
CL2008003138A1 (en) 2009-03-06
WO2009053443A3 (en) 2009-09-24
TW200934477A (en) 2009-08-16

Similar Documents

Publication Publication Date Title
RU2611437C2 (en) Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
CL2012001501A1 (en) Co-crystal consisting of agomelatine and an organic acid that has a solid state at room temperature; preparation procedures; pharmaceutical composition; and use in the treatment of disorders of the melatoninergic system such as stress, sleep disorders and generalized anxiety disorders, among others.
HRP20170095T1 (en) New crystalline form iii of agomelatin, the process for its preparation and pharmaceutical compositions containing it
HRP20161672T1 (en) New crystalline form vi of agomelatine, method of preparation and pharmaceutical compositions thereof
JP7074750B2 (en) Carbamoyl phenylalaninol compounds and their use
CN101790374A (en) Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
HRP20201405T1 (en) 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
TWI453013B (en) Use of n-(2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)-3,3-dimethyl-butyramide and medicament comprising said compound
CL2011000137A1 (en) Use of compounds derived from 4,5-dihydro-oxazol-2-ylamine to treat anxiety disorders, bipolar disorders, schizophrenia, neurological diseases, epilepsy, migraine, metabolic disorders, cardiovascular disorders, among others; compounds derived from 4,5-dihydroxazol-2-ylamino; synthesis process
CN1248966A (en) Aminobenzophenones as inhibitors of interleukin and TNF
NI200700084A (en) USE OF AGOMELATINE FOR THE OBTAINING OF MEDICINES FOR THE TREATMENT OF THE GENERALIZED ANXIETY DISORDER
AR069003A1 (en) INDOLINA COMPOUNDS, THEIR USES IN THE PREPARATION OF MEDICINES AND THEIR USES FOR THE TREATMENT OF MELATONINERGIC ALTERATIONS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND USE OF THE PHARMACEUTICAL COMPOSITION TO PREPARE A MEDICINAL PRODUCT
RU2012121684A (en) OXAZOLINE DERIVATIVES FOR THE TREATMENT OF CNS DISEASES
AR070951A1 (en) INDANO COMPOUNDS, THEIR USES FOR THE PREPARATION OF MEDICINES AND THEIR USES FOR THE TREATMENT OF MELATONINERGIC ALTERATIONS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
JP2015521642A5 (en)
NO20084865L (en) Treatment of pain disorders with trans 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-1-naphthalenamine and its formamide
AR069004A1 (en) COMPOUNDS OF 2,3-DIHIDRO-BENZOFURAN ITS USES FOR THE PREPARATION OF MEDICINES AND ITS USES FOR THE TREATMENT OF MELATONINERGIC ALTERATIONS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
JP2011529477A5 (en)
JP2011500763A5 (en)
ES2363565T3 (en) USEFUL REPLACED ACETOPHENONS AS PDE INHIBITORS 4.
AR070003A1 (en) NAFTALENIC DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2015521643A5 (en)
AR069002A1 (en) PHENYL PIRROLIDINE COMPOUNDS, THEIR USES FOR THE PREPARATION OF MEDICINES AND THEIR USES FOR THE TREATMENT OF MELATONINERGIC CHANGES, AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM
HRP20090632T1 (en) New naphthalene derivatives, method of preparing same and pharmaceutical compositions containing them
AR070004A1 (en) NAFTALENIC DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Legal Events

Date Code Title Description
FB Suspension of granting procedure